BioCentury on BioBusiness,
Why NIH, companies now eschew India for clinical trials
Related tables, figures and sidebars
India's clinical trial vacuum
Monday, July 29, 2013
NIH's recent decision to suspend or delay clinical
studies in India is a consequence of a clumsy rule change hastily implemented
by the country's regulatory authority. Stakeholders in industry and the
clinical community in India agree on a solution proposed by an advisory
committee to the Drug
Controller General of India, but opinions vary as to whether it will be
months or years before the government sees fit to address the issue.
In January, India's Ministry
of Health and Family Welfare published new rules governing the conduct
of clinical trials in an effort to ensure patient safety after a rash of media
reports and subsequent litigation related to clinical trial deaths led the
country's Supreme Court to intervene by directing the ministry to make reforms.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2014 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]